Device Trial Radar · NCT05582018
Safety and Effectiveness of BioTraceIO 360 for Planning, Monitoring and Assessment of Liver Tissue Ablation Procedures
Last checked: Nov 19, 2026Latest source record: Sep 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
4
Actual
Start
Sep 5, 2023
Primary completion
Apr 15, 2024
Study completion May 15, 2024
Sponsor
- Lead sponsor
- Techsomed Medical Technologies LTDNot on our public-company list
- Sponsor type
- Industry
- First posted
- Oct 17, 2022
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Pilot study planned to demonstrate the safety and effectiveness of the use of BioTraceIO 360 for Planning, Monitoring and Assessment of liver tissue ablation procedures Multi-center (up to 5 investigational sites) prospective single-arm clinical investigation. Sample size - 30 subjects.
Conditions
- Hepatocellular Carcinoma
- Metastatic Liver Cancer
Interventions
BioTraceIO 360Device
Use of the device for planning, monitoring and assessment of liver tissue ablations
Primary outcomes
What the sponsor says the trial is designed to measure.
- EffectivenessTime frame: 1 year
- SafetyTime frame: 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Einstein Medical Center
Philadelphia, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.